Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Cladribine vs IV Cladribine in HCL or T-PLL
NCT06021600Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cladribine in hairy cell leukemia (HCL) and T-cell prolymphocytic leukemia (T-PLL) (3 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Area Under the Curve, Maximum Concentration and 1 more. Started Oct 2023; status: terminated.
02
Drugs
cladribine
03
Conditions
hairy cell leukemia (HCL)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT06021600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021600.